Evidence map›Paper›PMID 30872568›Full record

ReviewExperimental & molecular medicine2019

Extracellular vesicles in onco-nephrology.

Chiara Gai, Margherita A C Pomatto, Cristina Grange, Maria Chiara Deregibus, Giovanni Camussi

Open access · goldAbstract readReview
In one paragraph

Review in Experimental & molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2023
    Article
  9. Review
  10. Exosomes in the Diagnosis and Treatment of Renal Cell Cancer.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  16. Article
  17. Extracellular Vesicles in the Tumour Microenvironment: Eclectic Supervisors.International journal of molecular sciences · 2020
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chiara GaiStem Cell Laboratory, Department of Medical Sciences, University of Turin, Turin, Italy.
Margherita A C PomattoStem Cell Laboratory, Department of Medical Sciences, University of Turin, Turin, Italy.
Cristina GrangeStem Cell Laboratory, Department of Medical Sciences, University of Turin, Turin, Italy.
Maria Chiara Deregibus2i3T Scarl, University of Turin, Turin, Italy.
Giovanni CamussiStem Cell Laboratory, Department of Medical Sciences, University of Turin, Turin, Italy. giovanni.camussi@unito.it.
University of Turin · IT

Funding

Biotechnology and Biological Sciences Research Council BB/M024393/1
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are important mediators of intercellular communication in cancer and in normal tissues. EVs transfer biologically active molecules from the cell of origin to recipient cells. This review summarizes the studies on EVs derived from renal cell carcinoma and from a subpopulation of CD105-positive renal cancer stem cells. While EVs from renal cell carcinoma show mild biological activity, EVs from renal cancer stem cells enhance tumor angiogenesis and metastasis formation. The effect is probably due to the transfer of proangiogenic RNA cargo to endothelial cells, which acquire an activated angiogenic phenotype. In vivo, treatment with EVs favors the formation of a premetastatic niche in the lungs. Moreover, EVs derived from renal cancer stem cells modify gene expression in mesenchymal stromal cells, enhancing the expression of genes involved in matrix remodeling, cell migration, and tumor growth. Mesenchymal stromal cells preconditioned with tumor EVs and then coinjected in vivo with renal cancer cells support tumor growth and vessel formation. Finally, tumor EVs promote tumor immune escape by inhibiting the differentiation process of dendritic cells and the activation of T cells. Thus, tumor-derived EVs act on the microenvironment favoring tumor aggressiveness, may contribute to angiogenesis through both direct and indirect mechanisms and are involved in tumor immune escape.

Indexed as

AnimalsCarcinoma, Renal CellExtracellular VesiclesGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMesenchymal Stem CellsNeoplastic Stem CellsNeovascularization, PathologicRNATumor MicroenvironmentRNA

Identifiers

PMID30872568
PMCPMC6418250
OpenAlexW2922151020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.